Theravance Biopharma Inc. (TBPH)

Name: Theravance Biopharma Inc. (TBPH) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Theravance Biopharma Inc. (TBPH)

Stock Card

$17.07

$0.04 (0.23%)

As on 02-Sep-2026 16:00EDT

Market cap

$885 Mln

Revenue (TTM)

$104 Mln

P/E Ratio

16.4

P/B Ratio

3.1

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Theravance Biopharma (TBPH) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 17.03 High: 17.08

52 Week Range

Low: 13.08 High: 21.03

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

8.6
Debt to Equity

0
Book Value

$--
EPS

$1
Face value

--
Shares outstanding

51,918,754

10 Years Aggregate

CFO

$-1,667.37 Mln

EBITDA

$-1,738.41 Mln

Net Profit

$-1,972.77 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Theravance Biopharma (TBPH)	-8.8	1.2	7.1	23.0	20.3	15.7	-5.1
BSE Sensex^*	-10.1	-2.5	2.0	-5.0	5.2	5.7	10.3
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Sep-2026 | *As on 03-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Theravance Biopharma (TBPH)	98.8	0.2	1.5	-37.8	-31.4	1.2
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Theravance Biopharma (TBPH)	17.1	885.2	104.3	53.8	61.6	18.4	16.4	3.1
Aptorum Group Limited Class A - ADR	8.4	0.6	1.0	-5.7	0.0	-49	--	0.3

Shareholding Pattern

View Details

About Theravance Biopharma (TBPH)

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary... disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Read more

Chairman & CEO

Mr. Rick E. Winningham M.B.A.
Chairman & CEO

Mr. Rick E. Winningham M.B.A.
Headquarters

South San Francisco, CA
Website

https://www.theravance.com

FAQs for Theravance Biopharma (TBPH)

What is the current share price of Theravance Biopharma Inc (TBPH) Today?

The share price of Theravance Biopharma Inc (TBPH) is $17.07 (NASDAQ) as of 02-Sep-2026 16:00 EDT. Theravance Biopharma Inc (TBPH) has given a return of 20.28% in the last 3 years.

What is the current PB & PE ratio of Theravance Biopharma Inc (TBPH)?

The P/E ratio of Theravance Biopharma Inc (TBPH) is 16.39 times as on 28-Aug-2026.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	9.37	3.35
2024	-8.22	2.64
2023	-10.06	2.61
2022	0.87	1.71
2021	-4.10	-2.41

What is the 52 Week High and Low of Theravance Biopharma Inc (TBPH)?

The 52-week high and low of Theravance Biopharma Inc (TBPH) are Rs 21.03 and Rs 13.08 as of 03-Sep-2026.

What is the market cap of Theravance Biopharma Inc (TBPH)?

Theravance Biopharma Inc (TBPH) has a market capitalisation of $ 885 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Theravance Biopharma Inc (TBPH)?

Before investing in Theravance Biopharma Inc (TBPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.